-+ 0.00%
-+ 0.00%
-+ 0.00%

Journey Medical Q1 FY26 net loss narrows to $2.2 million; revenue rises 21% to $16 million

PUBT·05/13/2026 20:06:00
Listen to the news
Journey Medical Q1 FY26 net loss narrows to $2.2 million; revenue rises 21% to $16 million
  • Journey Medical posted first-quarter revenue of USD 16 million, up 21% from a year earlier.
  • Net loss narrowed to USD 2.23 million, or USD 0.08 per share.
  • Gross margin slipped 2.5 percentage points to 61% on a USD 1.3 million non-cash charge tied to an API inventory write-down.
  • Emrosi revenue reached USD 6.3 million, while prescriptions totaled 29,968.
  • Secured a contract with the third-largest US group purchasing organization for Emrosi, expanding access to about 85% of commercial lives; CEO Claude Maraoui cited rising payer coverage, refill rates, and prescriber growth.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.